Abstracts tagged "psoriatic arthritis and rheumatoid arthritis (RA)"

Abstract Number: 974 • 2012 ACR/ARHP Annual Meeting
Identification of Susceptibility Loci for Inflammatory Arthritis
K. J. A. Steel¹, Anne Hinks², John Bowes³, Joanna Cobb², Edward Flynn⁴, Carl D. Langefeld⁵, Sampath Prahalad⁶, Johannes Peter Haas⁷, John F. Bohnsack⁸, Stephen Guthery⁸, Anne Barton¹, Susan D. Thompson⁹ and Wendy Thomson¹, ¹Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom, ²Arthritis Research UK Epidemiology Unit, Manchester Academic Health Sciences Centre, Institute of Inflammation and Repair, The University of Manchester, Manchester, United Kingdom, ³Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, ⁴Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester Academy of Health Sciences, Manchester, United Kingdom, ⁵Department of Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, NC, ⁶Pediatrics, Emory Children's Center, Atlanta, GA, ⁷Childrens Hospital, Erlangen, Germany, ⁸Department of Pediatrics,, University of Utah, Salt Lake City, ⁹Department of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: One of the principal findings of genome wide association studies in autoimmune diseases has been the substantial overlap of genetic susceptibility loci identified. This…
Abstract Number: 562 • 2012 ACR/ARHP Annual Meeting
Prevalence and Predictors of Significant Liver Fibrosis in Methotrexate Treated Rheumatoid and Psoriatic Arthritis Patients Using Transient Elastography (fibroscan)
WC Chan¹, ML Yip² and CK Loo¹, ¹Division of Gastroenterology and Hepatology, Department of Medicine, Kwong Wah Hospital, Kowloon, Hong Kong, ²Division of Rheumatology, Department of Medicine, Kwong Wah Hospital, Kowloon, Hong Kong
Background/Purpose: Methotrexate ( MTX ) is an anchor drug in the treatment of Rheumatoid ( RA ) and Psoriatic arthritis ( PSA )and is the…
Abstract Number: 543 • 2012 ACR/ARHP Annual Meeting
Wnt Pathway Inhibitors in Patients with Psoriatic and Rheumatoid Arthritis Treated with Anti-TNF Therapy
Agnes Szentpetery¹, Harjit P. Bhattoa², Peter Antal-Szalmas², Zoltan Szekanecz³ and Oliver M. FitzGerald⁴, ¹Rheumatology, Department of Rheumatology, St. Vincent's University Hospital, Dublin, Ireland, ²Laboratory Medicine, Department of Laboratory Medicine, University of Debrecen, Medical and Health Science Center, Debrecen, Hungary, ³Rheumatology, Department of Rheumatology, University of Debrecen Medical and Health Sciences Center, Debrecen, Hungary, ⁴Rheumatology, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland
Background/Purpose: Both rheumatoid arthritis (RA) and psoriatic arthritis (PsA) are characterised by bone erosion but aberrant bone formation is also a feature in PsA. Wnt…
Abstract Number: 2614 • 2012 ACR/ARHP Annual Meeting
The Risk of Diabetes in Psoriatic Arthritis and Rheumatoid Arthritis
Maureen Dubreuil¹, Young Hee Rho², Ada Man¹, Yanyan Zhu³, Yuqing Zhang², Thorvardur Love⁴, Alexis Ogdie⁵, Joel Gelfand⁶ and Hyon Choi⁷, ¹Rheumatology, Boston University School of Medicine, Boston, MA, ²Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA, ³Department of Biostatistics, Boston University School of Public Health, Department of Biostatistics, Boston University School of Public Health, Boston, MA, ⁴Landspitali University Hospital, Reykjavik, Iceland, ⁵Rheumatology and Epidemiology, University of Pennsylvania, Philadelphia, PA, ⁶University of Pennsylvania., Philadelphia, PA, ⁷Division of Rheumatology, Allergy, and Immunology Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: The potential impact of psoriatic arthritis (PsA) and rheumatoid arthritis (RA) on the risk of incident diabetes remains unclear. Studies have shown that patients…
Abstract Number: 2559 • 2012 ACR/ARHP Annual Meeting
Mortality in Patients with Psoriatic Arthritis Compared to Patients with Rheumatoid Arthritis, Psoriasis Alone, and the General Population
Alexis Ogdie¹, Kevin Haynes², Andrea Troxel², Thorvardur Love³, Hyon K. Choi⁴ and Joel Gelfand⁵, ¹Rheumatology and Epidemiology, University of Pennsylvania, Philadelphia, PA, ²Clinical Epidemiology and Biostatistics, University of Pennsylvania., Philadelphia, PA, ³Landspitali University Hospital, Reykjavik, Iceland, ⁴Section of Rheumatology and the Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA, ⁵University of Pennsylvania., Philadelphia, PA
Background/Purpose: Conflicting reports of the mortality risk among patients with psoriatic arthritis (PsA) exist in the literature, however excess mortality has been presumed given the…
Abstract Number: 2221 • 2012 ACR/ARHP Annual Meeting
Major Adverse Cardiovascular Events Are More Common in Rheumatoid Arthritis Than in Psoriatic Arthritis and Are Associated with Different Risk Factors
Allen P. Anandarajah¹, Katherine C. Saunders², George W. Reed³, Alina U. Onofrei³, Jeffrey D. Greenberg⁴ and Christopher T. Ritchlin⁵, ¹Dept of Rheumatology, Univ of Rochester Medical Ctr, Rochester, NY, ²Corrona, LLC., Southborough, MA, ³University of Massachusetts Medical School, Worcester, MA, ⁴NYU Hospital for Joint Diseases, New York, NY, ⁵Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY
Background/Purpose: Rheumatoid Arthritis (RA) is associated with increased cardiovascular mortality and morbidity rates. Similarly several studies have reported an increased risk for cardiovascular events in…
Abstract Number: 1925 • 2012 ACR/ARHP Annual Meeting
Patient Satisfaction and Experience with Golimumab, Adalimumab, and Etanercept for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis
Susan Bolge¹, Helen Eldridge², Dilesh Doshi¹, Lorie Ellis³, Barbara Roland⁴ and John Woelfel⁴, ¹Janssen Scientific Affairs, LLC, Horsham, PA, ²Janssen Services, LLC., Titusville, NJ, ³Health Economics & Outcomes Research, Janssen Scientific Affairs, LLC, Horsham, PA, ⁴The Dominion Group, Reston, VA
Title: Patient Satisfaction and Experience with Golimumab, Adalimumab, and Etanercept for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis Background/Purpose: Golimumab (GLM), adalimumab…
Abstract Number: 1851 • 2012 ACR/ARHP Annual Meeting
Exploring the Relationship of Anti-Tumor Necrosis Factor Drugs and Methicillin Resistant Staphylococcus Aureus Nasal Colonization in Patients with Rheumatologic Conditions and Psoriasis
Daniel E. Kreutz¹, Santosh P. Reddy¹, Guy P. Fiocco², Colleen Colbert³ and Juhee Song⁴, ¹Internal Medicine, Scott & White Healthcare/Texas A&M University, Temple, TX, ²Division of Rheumatology, Scott & White Clinic, Temple, TX, ³Graduate Education, Scott & White Healthcare/Texas A&M University, Temple, TX, ⁴Statistics, Scott & White Healthcare/Texas A&M University, Temple, TX
Background/Purpose: Infection with methicillin-resistant Staphylococcus aureus (MRSA) is a source of significant morbidity/mortality. Health-care entities spend large amounts to prevent spread of MRSA. Most MRSA…
Abstract Number: 1825 • 2012 ACR/ARHP Annual Meeting
Work Disability and Work Limitations in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Are Equal and Increase with Comorbidities
Chanseok Rhee¹, Janet E. Pope², Andrew E. Thompson³, Nicole G. H. Le Riche⁴, Gina Rohekar⁵ and Sherry Rohekar⁵, ¹School of Medicine and Dentistry, Schulich School of Medicine and Dentisty, Western University, London, ON, Canada, ²Medicine/Rheumatology, St. Joseph Health Care London, University of Western Ontario, London, ON, Canada, ³Rheumatology, St. Josephs Health Ctr, London, ON, Canada, ⁴Department of Medicine, St. Joseph's Hospital, London, ON, Canada, ⁵Rheumatology, St. Joseph's Hospital, London, ON, Canada
Background/Purpose: Few studies directly compare work disability (WD) and work productivity losses in different forms of inflammatory arthritis (IA) such as rheumatoid arthritis (RA), psoriatic…
Abstract Number: 1835 • 2012 ACR/ARHP Annual Meeting
Prescription of Biologics in Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA) and Ankylosing Spondylitis (AS) in 4 Norwegian Regions 2002-2011: A Study of Prescription Rates and Baseline Disease Activity
Elisabeth Lie¹, Karen M. Fagerli², Knut Mikkelsen³, Åse S. Lexberg⁴, Erik Rødevand⁵, Till Uhlig¹ and Tore K. Kvien¹, ¹Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Department of Rheumatology, Diakonhjemmet Hospital, Department of Rheumatology, Oslo, Norway, Oslo, Norway, ³Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway, ⁴Dept. of Rheumatology, Vestre Viken Hospital, Drammen, Norway, ⁵Dept. of Rheumatology, St. Olavs Hospital, Trondheim, Norway
Background/Purpose: Biologics have constituted a major advance in the treatment of RA, PsA and AS. In Norway access to these therapies has been good since…
Abstract Number: 1355 • 2012 ACR/ARHP Annual Meeting
Hand Bone Loss Is Arrested in Early Psoriatic Arthritis but Not in Rheumatoid Arthritis Following Anti-Rheumatic Treatment Assessed by Digital X-Ray Radiogrammetry
Agnes Szentpetery¹, Muhammad Haroon², Phil Gallagher³, Martina Cooney⁴, Eric J. Heffernan⁵ and Oliver M. FitzGerald¹, ¹Rheumatology, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland, ²Dublin Academic Medical Center, St. Vincent's University Hospital, Dublin, Ireland, ³Rheumatology, Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland, ⁴Rheumatology, Department of Rheumatology, St. Vincent's University Hospital, Dublin, Ireland, ⁵Radiology, Department of Radiology, St. Vincent's University Hospital, Dublin, Ireland
Background/Purpose: Periarticular bone loss is an early feature of both psoriatic arthritis (PsA) and rheumatoid arthritis (RA). Digital X-ray radiogrammetry (DXR) is a sensitive method…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].